Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

226,291-226,320 of 319,975

filter-aware
22
The table shows revenue, margins, expenses, and profit metrics with year-over-year percentage changes.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Satisfaction1 hit
23
The chart illustrates a bridge from 21,055 M€ in 2022 to 22,802 M€ in 2023.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · ActionLoop · Before After1 hit
24
The table shows a breakdown of financial costs and adjustments, with a total net financial result change of -47 million euros.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · ActionLoop · Before After1 hit
25
The slide uses a stacked bar chart to represent the balance sheet structure.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
26
The table breaks down cash flow from operations, net cash from operating activities, and operating free cash flow.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
27
The chart combines a bar chart for debt (in millions of euros) and a line chart for the gearing percentage.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
28
The 2023 dividend is subject to approval at the Annual General Meeting.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations Beat · Action1 hit
29
The slide features a high-fashion photograph of a woman with a Louis Vuitton handbag, likely used as a stylistic transition or section break.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations 1 hit
30
The slide presents two distinct tables stacked vertically, comparing year-over-year performance.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations 1 hit
31
Includes a disclaimer regarding rounding discrepancies in totals.LVMH | Results Presentation Deck | 31 slides · LVMH
Conference presentation Investor relations 1 hit
01
Slide 1
The background image appears to be a microscopic view of chromosomes or cellular structures, reinforcing the 'telomere' focus.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
02
MAIA Biotechnology | Investor Presentation Deck | 31 slidesMAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
03
The slide outlines the status of THIO-101, 102, and 103, highlighting FDA designations and clinical trial progress.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · The Ask1 hit
04
The slide uses a custom timeline/pipeline layout to show drug development stages.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
05
MAIA Biotechnology | Investor Presentation Deck | 31 slidesMAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
06
The slide uses a three-column layout with circular callouts to emphasize demographic trends and disease prevalence.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
07
This is a transition or thesis slide emphasizing competitive differentiation.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
The slide illustrates a sequential therapeutic approach: THIO treatment followed by CPI therapy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
09
Slide highlights a strategic partnership/traction milestone.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
10
The chart demonstrates tumor volume reduction over time, highlighting the efficacy of the THIO + Atezo combination.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
11
The slide outlines a multi-part clinical trial process from Part A (Safety) through Part B (Efficacy/Dose Selection) to a planned Expansion phase.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
12
The table compares a standard of care (Cyramza), a regulatory benchmark, and the company's own drug candidate (THIO-101).MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
13
Data cut of ongoing study THIO-101 as of 13Nov2023.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
14
The slide uses a specific medical study to justify a change in clinical trial endpoint strategy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
15
Data cut as of 13Nov2023.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
16
The chart tracks individual patient timelines, including disease progression, partial responses, and study outcomes.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
17
The slide outlines a multi-part clinical trial design (basket/umbrella) for a biotech drug candidate.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
18
The slide presents two line charts showing tumor volume reduction over time, highlighting 100% complete response (CR) and resistance to tumor rechallenge.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
19
The slide shows two line charts comparing tumor volume reduction across different treatment regimens in mouse models.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
20
The chart shows tumor volume over time, with the THIO group reaching 100% complete response (CR).MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit